ImmunityBio (IBRX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of ImmunityBio (IBRX)
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
Key Insights
Critical company metrics and information
Share Price
$4.68Market Cap
$3.26 BillionTotal Outstanding Shares
696.83 Million SharesTotal Employees
672Dividend
No dividendIPO Date
March 10, 2021SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.immunitybio.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities, Continuing | $-19.83 Million |
Net Cash Flow From Financing Activities | $375.24 Million |
Net Cash Flow, Continuing | $-65.95 Million |
Net Cash Flow From Investing Activities | $-19.83 Million |
Net Cash Flow From Financing Activities, Continuing | $375.24 Million |
Net Cash Flow | $-65.95 Million |
Net Cash Flow From Operating Activities, Continuing | $-421.36 Million |
Net Cash Flow From Operating Activities | $-421.36 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Income/Loss From Continuing Operations After Tax | $-587.88 Million |
Nonoperating Income/Loss | $-227.75 Million |
Income/Loss From Equity Method Investments | $0.00 |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Selling, General, and Administrative Expenses | $160.16 Million |
Research and Development | $206.46 Million |
Diluted Average Shares | $742.58 Million |
Diluted Earnings Per Share | $0.91 |
Benefits Costs and Expenses | $595.25 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $86000.00 |
Net Income/Loss Available To Common Stockholders, Basic | $-587.79 Million |
Income Tax Expense/Benefit | $40000.00 |
Basic Earnings Per Share | $0.90 |
Net Income/Loss Attributable To Parent | $-587.79 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Net Income/Loss | $-587.88 Million |
Operating Expenses | $367.50 Million |
Basic Average Shares | $738.90 Million |
Operating Income/Loss | $-360.17 Million |
Income/Loss From Continuing Operations Before Tax | $-587.92 Million |
Revenues | $7.33 Million |
Costs And Expenses | $595.25 Million |
Interest Expense, Operating | $120.72 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Liabilities | $1.11 Billion |
Fixed Assets | $139.28 Million |
Equity Attributable To Noncontrolling Interest | $986000.00 |
Current Liabilities | $60.96 Million |
Equity Attributable To Parent | $-745.15 Million |
Other Non-current Assets | $62.13 Million |
Liabilities And Equity | $364.57 Million |
Inventory | $1.96 Million |
Current Assets | $163.15 Million |
Assets | $364.57 Million |
Noncurrent Liabilities | $1.05 Billion |
Other Current Assets | $161.19 Million |
Noncurrent Assets | $201.42 Million |
Equity | $-744.16 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.